<DOC>
	<DOCNO>NCT01416155</DOCNO>
	<brief_summary>The primary objective study evaluate long-term safety tolerability profile BG00002 ( natalizumab ) Japanese participant relapsing-remitting multiple sclerosis ( RRMS ) . The secondary objective study evaluate long-term efficacy profile BG00002 Japanese participant RRMS .</brief_summary>
	<brief_title>Extension Study Evaluate Safety Efficacy Natalizumab Japanese Participants With Relapsing-Remitting Multiple Sclerosis</brief_title>
	<detailed_description>This multicenter , long-term , open-label , extension study participant successfully complete Study 101MS203 ( NCT01440101 ) .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Key Ability understand purpose risk study provide sign date informed consent authorization require local law . Subjects participate complete protocolrelated evaluation Week 24 Study 101MS203 ( NCT01440101 ) . Subjects participate study 101MS204 ( NCT01416155 ) participate either open label pharmacokineticspharmacodynamics study placebocontrolled study natalizumab 300 mg q4wks ( part A B study 101MS203 , respectively ) . Subjects childbearing potential must practice effective contraception study willing able continue contraception 12 week last dose study treatment . Must willing remain free concomitant immunosuppressive immunomodulatory treatment ( include interferon beta [ IFNβ ] longterm systemic corticosteroid ) duration study . Key Exclusion Criteria Medical History Any significant change medical history since Study 101MS203 ( NCT01440101 ) , include laboratory test , current clinically important condition opinion Investigator would exclude subject 's participation previous study . The Investigator must rereview subject 's medical fitness participation consider disease would preclude treatment . Subjects Study 101MS203 ( NCT01440101 ) discontinue study treatment due adverse event . Subjects determine persistently positive antiBG0002 antibody base prior test . Treatment History Treatment follow medication last dose study treatment Study 101MS203 ( NCT01440101 ) start study : intravenous immunoglobulin ( IVIg ) , plasmapheresis , cytapheresis , immunosuppressant medication ( e.g. , mitoxantrone , azathioprine , cyclophosphamide , methotrexate , cyclosporine , FTY720 ) , immunomodulatory medication ( include IFNβ glatiramer acetate [ GA ] ) total lymphoid irradiation , cladribine , Tcell Tcell receptor vaccination , murine protein , therapeutic monoclonal antibody , 4aminopyridine related product . Miscellaneous For female subject , unless postmenopausal least 1 year surgically sterile ( include tubal ligation ) , unwillingness practice effective contraception , define Investigator , study . Women consider become pregnant study exclude . Female subject currently pregnant breast feeding , include subject whose pregnancy test positive Week 0 . Unwillingness inability comply requirement protocol , include presence condition ( physical , mental , social ) likely affect subject 's ability comply study protocol . Subjects condition , clinical finding , reason opinion Investigator and/or Sponsor make subject unsuitable enrollment study . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>